Floatz logo

prt7732

SMARCA4 Mutation

Prelude TherapeuticsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the SMARCA4 Mutation cohort.

Asset / SponsorPhaseRating
Plx-61639
Plexium, Inc.
Phase 1CC

Same molecule, other indications

prt7732 is also rated in:

gastric squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Gastroesophageal Junction Squamous Cell CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →